PCSK9 and acute coronary syndrome: Recent research has shifted its focus toward the feasibility of applying PCSK9 inhibition therapy to patients with acute coronary syndrome (ACS) as soon as possible, as both serum and ischemic myocardial PCSK9 levels surge rapidly during ACS, potentially contributing to acute inflammatory reactions (Cariou et al., 2017; Ding et al., 2018; Ferri et al., 2022).